| Field | Specification |
|---|---|
| Mfr No | |
| Clonality | |
| Concentration | |
| Conjugate | |
| Host | |
| Immunogen | Synthetic peptide of human GRIK2 |
| Isotype | |
| Product Type | |
| Shipping | |
| Storage | |
| UniProt # |
Product Overview
GRIK2 (Glutamate Ionotropic Receptor Kainate Type Subunit 2) is a Protein Coding gene. Diseases associated with GRIK2 include Autosomal Recessive Non-Syndromic Intellectual Disability and Spinocerebellar Ataxia 11. Among its related pathways are CREB Pathway and Presynaptic function of Kainate receptors. GO annotations related to this gene include protein homodimerization activity and ubiquitin protein ligase binding. An important paralog of this gene is GRIK3.Glutamate receptors are the predominant excitatory neurotransmitter receptors in the mammalian brain and are activated in a variety of normal neurophysiologic processes. This gene product belongs to the kainate family of glutamate receptors, which are composed of four subunits and function as ligand-activated ion channels. The subunit encoded by this gene is subject to RNA editing at multiple sites within the first and second transmembrane domains, which is thought to alter the structure and function of the receptor complex. Alternatively spliced transcript variants encoding different isoforms have also been described for this gene. Mutations in this gene have been associated with autosomal recessive mental retardation.
Validated Applications & Recommended Dilutions
| Application | Recommended Dilution |
|---|---|
| Immunohistochemistry | IHC 1:25-1:100 |
Antibody Specifications
| Target | GRIK2 |
|---|---|
| Host Species | Rabbit |
| Clonality | Polyclonal |
| Isotype | IgG |
| Conjugate | Unconjugated |
| Purification | Antigen Affinity Purification |
| Concentration | 1.56 mg/mL |
Immunogen
Synthetic peptide of human GRIK2 UniProt: Q13002.
Species Reactivity & Cross-Reactivity
Validated for: Human, Mouse, Rat. Verify suitability in your sample type prior to use. For species or applications not listed in the datasheet, consult our technical team before purchase.
Storage & Handling
Store at -20℃ Valid for 12 months. Avoid freeze / thaw cycles.
Storage Buffer: PBS with 0.05% NaN3 and 40% Glycerol,pH7.4
Related Products
Browse additional antibodies targeting GRIK2 and complementary reagents — including secondary antibodies, blocking buffers, and detection kits — available through BioHippo.
For IHC-P, heat-induced epitope retrieval (HIER) is typically required. Recommended starting conditions: citrate buffer pH 6.0 (microwave or pressure cooker, ~20 min) for rodent samples; EDTA buffer pH 9.0 for human clinical samples. After retrieval, allow sections to cool gradually before proceeding to blocking. Include a GRIK2-positive tissue control (confirmed by literature or database expression data) and a negative isotype control in every run. Recommended dilution: IHC 1:25-1:100. Refer to the product datasheet for any target-specific retrieval guidance.
This antibody has been experimentally validated in: Human, Mouse, Rat. Cross-reactivity with other species has not been systematically evaluated. If your sample species is not listed, assess immunogen sequence homology to your target species ortholog. The immunogen used is: "Synthetic peptide of human GRIK2" — higher sequence identity between species increases the probability of cross-reactivity, but experimental validation with appropriate controls is necessary before drawing scientific conclusions.
Store at -20℃ Valid for 12 months. Avoid freeze / thaw cycles. Storage Buffer: PBS with 0.05% NaN3 and 40% Glycerol,pH7.4. To maintain antibody activity, avoid repeated freeze-thaw cycles. Aliquot into single-use volumes before first freeze. If working with the antibody frequently, keep a working stock at 4°C for up to 4 weeks — add 0.02% sodium azide to the working stock as a bacteriostatic agent if azide is not already present in the buffer. Monitor performance against a validated positive control when transitioning between storage aliquots or lots.
Polyclonal antibodies are produced from immunized animals and may exhibit some degree of lot-to-lot variation in titer, background, and sensitivity. Each production lot is tested for performance against established acceptance criteria. When transitioning to a new lot, run a side-by-side pilot comparison against your previous lot using a validated positive control sample before updating your standard protocol. If significant performance differences are observed, contact our technical support team — titer adjustments may resolve the issue in most cases.
Customization & Add-ons: Can't find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.